{
    "root": "e4b78c34-efde-4552-ae2a-c3ce006bb477",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "GUANFACINE"
    },
    "value": "20250521",
    "ingredients": [
        {
            "name": "GUANFACINE HYDROCHLORIDE",
            "code": "PML56A160O"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "FUMARIC ACID",
            "code": "88XHZ13131"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FD&C BLUE NO. 2--ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "guanfacine extended-release tablets indicated treatment attention deficit hyperactivity disorder ( adhd ) monotherapy adjunctive therapy stimulant medications [ ( 14 ) ] .",
    "contraindications": "• recommended dose : 1 mg 7 mg ( 0.05 0.12 mg/kg target weight based dose range ) daily morning evening based response tolerability ( 2.2 ) . • begin dose 1 mg daily adjust increments 1 mg/week ( 2.2 ) . • crush , chew break tablets swallowing ( 2.1 ) . • administer high-fat meals , increased exposure ( 2.1 ) . • substitute immediate-release guanfacine tablets mg-per-mg basis , differing pharmacokinetic profiles ( 2.3 ) . • switching immediate-release guanfacine , discontinue treatment titrate guanfacine extended-release tablet directed ( 2.3 ) . • discontinuing , taper dose decrements 1 mg every 3 7 days avoid rebound hypertension ( 2.5 ) .",
    "warningsAndPrecautions": "guanfacine extended-release tablets , usp supplied 1 mg , 2 mg , 3 mg , 4 mg strength follows : guanfacine extended-release tablets usp , 1 mg white white colored , round shaped tablets , debossed ‘ l657 ’ one side plain side . bottles 100 tablets child-resistant closure , ndc 62332-745-31 bottles 1000 tablets , ndc 62332-745-91 guanfacine extended-release tablets usp , 2 mg white white colored , caplet shaped tablets , debossed ‘ l658 ’ one side plain side . bottles 100 tablets child-resistant closure , ndc 62332-746-31 bottles 1000 tablets , ndc 62332-746-91 guanfacine extended-release tablets usp , 3 mg light green green colored , round shaped tablets , debossed ‘ l659 ’ one side plain side . bottles 100 tablets child-resistant closure , ndc 62332-747-31 bottles 1000 tablets , ndc 62332-747-91 guanfacine extended-release tablets usp , 4 mg light green green colored , caplet shaped tablets , debossed ‘ l660 ’ one side plain side . bottles 100 tablets child-resistant closure , ndc 62332-748-31 bottles 1000 tablets , ndc 62332-748-91 storage - store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "guanfacine contraindicated patients history hypersensitivity reaction guanfacine extended-release tablets inactive ingredients , products containing guanfacine . rash pruritus reported .",
    "indications_original": "Guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies (14)].",
    "contraindications_original": "• Recommended dose: 1 mg to 7 mg (0.05 to 0.12 mg/kg target weight based dose range) once daily in the morning or evening based on clinical response and tolerability ( 2.2 ). • Begin at a dose of 1 mg once daily and adjust in increments of no more than 1 mg/week ( 2.2 ). • Do not crush, chew or break tablets before swallowing ( 2.1 ). • Do not administer with high-fat meals, because of increased exposure ( 2.1 ). • Do not substitute for immediate-release guanfacine tablets on a mg-per-mg basis, because of differing pharmacokinetic profiles ( 2.3 ). • If switching from immediate-release guanfacine, discontinue that treatment and titrate with guanfacine extended-release tablet as directed ( 2.3 ). • When discontinuing, taper the dose in decrements of no more than 1 mg every 3 to 7 days to avoid rebound hypertension ( 2.5 ).",
    "warningsAndPrecautions_original": "Guanfacine extended-release tablets, USP are supplied in 1 mg, 2 mg, 3 mg, and 4 mg strength as follows:\n                  Guanfacine extended-release tablets USP, 1 mg are white to off white colored, round shaped tablets, debossed with ‘L657’ on one side and plain on other side.\n                  Bottles of 100 tablets with child-resistant closure, NDC 62332-745-31\n                  Bottles of 1000 tablets, NDC 62332-745-91\n                  \n                  Guanfacine extended-release tablets USP, 2 mg are white to off white colored, caplet shaped tablets, debossed with ‘L658’ on one side and plain on other side.\n                  Bottles of 100 tablets with child-resistant closure, NDC 62332-746-31\n                  Bottles of 1000 tablets, NDC 62332-746-91\n                  \n                  Guanfacine extended-release tablets USP, 3 mg are light green to green colored, round shaped tablets, debossed with ‘L659’ on one side and plain on other side.\n                  Bottles of 100 tablets with child-resistant closure, NDC 62332-747-31\n                  Bottles of 1000 tablets, NDC 62332-747-91\n                  \n                  Guanfacine extended-release tablets USP, 4 mg are light green to green colored, caplet shaped tablets, debossed with ‘L660’ on one side and plain on other side.\n                  Bottles of 100 tablets with child-resistant closure, NDC 62332-748-31\n                  Bottles of 1000 tablets, NDC 62332-748-91\n                  \n                  \n                     Storage - Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Guanfacine is contraindicated in patients with a history of a hypersensitivity reaction to guanfacine extended-release tablets or its inactive ingredients, or other products containing guanfacine. Rash and pruritus have been reported."
}